Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29999249 | 1.00 | TSHR (0.40) | TSHRIDO1L3MBTL1TP53CYP3A4 | |
| SCHEMBL1500773 | 0.89 | TSHR (0.50) | TSHRIDO1L3MBTL1TP53CYP3A4 | |
| SCHEMBL625710 | 0.84 | TSHR (0.41) | TSHRIDO1L3MBTL1TP53CYP3A4 | |
| SCHEMBL27798832 | 0.81 | IDO1 (0.37) | TSHRIDO1L3MBTL1 | |
| SCHEMBL642402 | 0.81 | IDO1 (0.40) | TSHRIDO1CYP3A4TRPA1ALDH1A1 | |
| SCHEMBL400236 | 0.81 | IDO1 (0.46) | TSHRIDO1CYP3A4TRPA1ALDH1A1 | |
| SCHEMBL114694 | 0.81 | — | — | |
| SCHEMBL28894230 | 0.80 | TSHR (0.40) | TSHRIDO1L3MBTL1TP53CYP3A4 | |
| SCHEMBL2732843 | 0.78 | ACHE (0.39) | TSHRIDO1L3MBTL1TP53CYP3A4 | |
| SCHEMBL1363469 | 0.78 | PNMT (0.46) | TSHRIDO1L3MBTL1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4448522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4288442-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | Faxian Therapeutics, LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023110958-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022170198-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC (US) | 2022-08-11 | — | — | WO | disclosed |
| CN-108440515-A | Substituted benzofuranyl and benzoxazole based compound and application thereof | 卡尔约药物治疗公司 | 2018-08-24 | — | — | CN | disclosed |
| CN-105492437-B | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | 卡尔约药物治疗公司 | 2018-05-11 | — | — | CN | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| WO-2007002214-A2 | ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| EP-1603880-A1 | QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-14 | — | — | EP | disclosed |
| US-20050261308-A1 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-11-24 | — | — | US | disclosed |
| US-6943169-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2004080969-A1 | QUINOLINONE / BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | ROCHE PALO ALTO LLC | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | USP7, USP28, USP1 | TSHR 4303/4885IDO1 1841/4885L3MBTL1 355/4885 |
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | NQO2, UGT1A8, UGT1A1 | TSHR 2498/4885IDO1 1120/4885L3MBTL1 4557/4885 |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, LIPC, PNLIP | TSHR 3993/4885IDO1 2862/4885L3MBTL1 1120/4885 |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | APP, BACE1, BACE2 | TSHR 4211/4885IDO1 2441/4885L3MBTL1 2065/4885 |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | TSHR 3913/4885IDO1 3885/4885L3MBTL1 1995/4885 |
| US-20050261308-A1 | Quinolinone derivatives and uses thereof | RECQL, NQO2, QRFPR | TSHR 1257/4885IDO1 1518/4885L3MBTL1 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.